Received Mar 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
product complaint; less than recommended dose administered/maybe only half of the dose; the rest was sprayed all over their arm; the rest was sprayed all over their arm; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete dose administered in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 07-MAR-2026, the patient received Shingrix. On 07-MAR-2026, an unknown time after receiving Shingrix, the patient experienced incomplete dose administered (Verbatim: less than recommended dose administered/maybe only half of the dose), occupational exposure via skin contact with product (Verbatim: the rest was sprayed all over their arm) and inadvertent exposure to vaccine (Verbatim: the rest was sprayed all over their arm). On an unknown date, the patient experienced pharmaceutical product complaint (Verbatim: product complaint). The outcome of the incomplete dose administered, occupational exposure via skin contact with product, inadvertent exposure to vaccine and pharmaceutical product complaint were not applicable. Additional Information: GSK receipt date: 09-MAR-2026 A healthcare provider administered a Shingrix dose, but the patient pulled away; they calculated that maybe only half of the dose had been delivered and the rest had been sprayed all over the patient's arm. The pharmacist did not have the patient's demographics or the vaccine lot number, but he knew the patient was older than 50 years of age. The batch number was not provided upon follow up with the reporter.